Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urinary casts

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Urinary casts. Displaying page 1 of 1.
    EudraCT Number: 2011-002159-32 Sponsor Protocol Number: 211LE201 Start Date*: 2012-03-30
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) BE (Completed) DE (Completed) ES (Prematurely Ended) HU (Completed) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003767-25 Sponsor Protocol Number: APL2-C3G-310 Start Date*: 2022-03-08
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolif...
    Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    21.1 10038359 - Renal and urinary disorders 10027168 Membranoproliferative glomerulonephritis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) CZ (Completed) BE (Completed) AT (Trial now transitioned) FR (Completed) PL (Completed) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004852-62 Sponsor Protocol Number: FARM7KWBZ4 Start Date*: 2009-02-09
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
    Full Title: Safety and clinical efficacy of abetimus sodium (LJP-394) in prevention of renal flares in patients with systemic lupus erythematosus and a history of renal disease.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028395 SOC
    9.1 10040970 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002068-29 Sponsor Protocol Number: ANCA_CGM Start Date*: 2019-10-24
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Nephrologie
    Full Title: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis
    Medical condition: ANCA vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004917-41 Sponsor Protocol Number: WX17801 Start Date*: 2005-09-05
    Sponsor Name:Aspreva International Ltd.
    Full Title: A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in s...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    4.1 10025140 Low
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) PT (Completed) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003230-93 Sponsor Protocol Number: CCFZ533X2202 Start Date*: 2018-05-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients wi...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000391-28 Sponsor Protocol Number: 951404713 Start Date*: 2017-09-20
    Sponsor Name:INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
    Full Title: A PHASE II, DOUBLE-BLIND, CONTROLLED, PARALLEL-ARM TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INFUSION OF ALLOGENIC MESENCHYMAL STEM CELLS IN LUPUS NEPHRITIS (LN)
    Medical condition: LUPUS NEPHRITIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003364-51 Sponsor Protocol Number: AUR-VCS-2012-01 Start Date*: 2014-10-24
    Sponsor Name:Aurinia Pharmaceuticals Inc.
    Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis
    Medical condition: Active lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002022-39 Sponsor Protocol Number: WA29748 Start Date*: 2015-09-24
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of Obinutuzumab in patients with ISN/RPS 2003 class III or IV Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000305-23 Sponsor Protocol Number: BOS161721-02 Start Date*: 2019-03-20
    Sponsor Name:Boston Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
    Medical condition: Systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-005535-24 Sponsor Protocol Number: ABROGATE-5527 Start Date*: 2016-06-07
    Sponsor Name:Univeristy of South Florida
    Full Title: Abatacept (CTLA4-Ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (Wegener's)
    Medical condition: Granulomatosis with polyangiitis (GPA; Wegener's granulomatosis)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10047889 Wegeners granulomatosis LLT
    19.0 100000004866 10047888 Wegener's granulomatosis LLT
    19.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000714-11 Sponsor Protocol Number: IM101-291 Start Date*: 2013-04-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticostero...
    Medical condition: Active Class III or IV lupus glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) ES (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001203-79 Sponsor Protocol Number: IM011021 Start Date*: 2017-12-04
    Sponsor Name:Bristol-Myers Squibb international Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017968 10042947 Systemic lupus erythematosus synd LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) DE (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-000674-73 Sponsor Protocol Number: LJP 394-90-14 Start Date*: 2006-08-11
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOS...
    Medical condition: Systemic lupus erythematosus patients with a history of renal disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042945 Systemic lupus erythematosus LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004047-86 Sponsor Protocol Number: AIS-A03 Start Date*: Information not available in EudraCT
    Sponsor Name:Alpine Immune Sciences, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPN-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10042946 Systemic lupus erythematosus rash PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    20.1 10022891 - Investigations 10067657 Systemic lupus erythematosus disease activity index increased PT
    20.0 10022891 - Investigations 10067658 Systemic lupus erythematosus disease activity index decreased PT
    20.1 10022891 - Investigations 10067659 Systemic lupus erythematosus disease activity index abnormal PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10080670 Systemic lupus erythematosus reactivation LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10073694 Lupus pleurisy PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10040968 SLE arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001796-14 Sponsor Protocol Number: CYTB323G12101 Start Date*: 2023-03-20
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).
    Medical condition: Systemic Lupus Erythematosus Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:10:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA